Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer Clinical research trials and Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer. Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer clinical trial. Test subjects typically obtain the finest healthcare available for their Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.

Home > "E" Clinical Trials Conditions > Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer



Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

For Condition: stage 1 prostate cancer
Status: Recruiting
Sponsor(s): Chao Family Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of eflornithine may be an effective way to prevent the development of prostate cancer. PURPOSE: Randomizedphase II trial to determine the effectiveness of eflornithine in preventing prostate cancer in patients who are at high risk of developing the disease.
Details: OBJECTIVES: - Compare the levels of polyamines (putrescine, spermidine, and spermine) and progression-related genes in the prostate tissue of patients at high genetic risk for prostate cancer treated with eflornithine (DFMO) vs placebo. - Determine the side effects of DFMO and compare them with the biological effect on the prostate gland in these patients. OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to age (35 to 60 vs 61 to 70) and presence of localized cancer (yes vs no). All patients receive oral placebo daily for 4 weeks. Patients who are compliant and take the placebo 5-7 days each week are randomized to one of two arms. - Arm I: Patients receive oral placebo daily. - Arm II: Patients receive high-dose oral eflornithine (DFMO) daily. Treatment continues for 1 year in the absence of unacceptable toxicity. PROJECTED ACCRUAL: A total of 100 patients (50 per arm) will be accrued for this study within 3 years.
Eligibility:
Study Type:  Interventional, Prevention
Minimum Age/Maximum Age: 35 Years/70 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Unaffected brother or first-degree cousin of a young (under age 70) prostate cancer proband with a family history (two or more first-degree relatives) of prostate cancer - No prior non-localized prostate cancer or previously diagnosed premalignant prostate disease PATIENT CHARACTERISTICS: Age: - 35 to 70 Performance status: - SWOG 0-1 OR - Karnofsky 70-100% Life expectancy: - At least 5 years Hematopoietic: - Hematocrit at least 35% - WBC at least 4,000/mm^3 with normal differential - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin less than 2.0 mg/dL - SGOT or SGPT less than 2 times normal Renal: - Creatinine less than 1.5 mg/dL - Less than 1+ protein, 0-3 casts, and 0-5 WBCs and RBCs in urine Gastrointestinal: - No medically mandated special diet that would preclude compliance with study participation - No documented or symptomatic gastric or duodenal ulcer disease within the past year Other: - No severe metabolic disorders or other life-threatening acute or chronic disease - No other invasive cancer within the past 5 years except nonmelanoma skin cancer - No predisposition to difficulties with wound healing or repair PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No concurrent chemotherapy Endocrine therapy: - At least 3 months since prior finasteride Radiotherapy: - No prior radiotherapy to pelvic area - No concurrent x-rays Surgery: - Not specified Other: - At least 3 months since prior chemoprevention agents - No aspirin or aspirin-containing products within 10 days prior to each study biopsy - No concurrent anticoagulants
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
ThomasAhlering,  Study Chair,  Chao Family Comprehensive Cancer Center

Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center *Recruiting*
Orange,  California,  92868
United States
Recruiting Thomas  Ahlering 714-456-8200


Additional Information:
Study ID Numbers:  CDR0000068110;  UCIRVINE-97-18,NCI-P00-0164,UCIRVINE-U01-CA-81886-01
Study Start Date: 
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006101

Other Stage 1 Prostate Cancer Studies:
1. Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients with Prostate Cancer

2. Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer

3. Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

4. Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

5. Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer

Related Studies:

Other stage 1 prostate cancer Clinical Trials
Other California Clinical Trials
Other Orange Clinical Trials

Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
Modify your Search

  Other stage 1 prostate cancer Clinical Trials
  Other California Clinical Trials
  Other Orange Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103